Status:
COMPLETED
Dose Finding Study for Effective Reversal of a Deep Rocuronium-induced Neuromuscular Block With Sugammadex in Morbidly Obese Patients
Lead Sponsor:
University Hospital, Ghent
Conditions:
Morbidly Obese Patients
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
During laparoscopic bariatric surgery, adequate muscle relaxation is important to maintain good surgical conditions. To achieve this muscle relaxation, neuromuscular transmission blocking agents, such...
Detailed Description
Flowchart : 72 participants Stratification BMI\<50 BMI \>50 Randomization Randomization TBW IBW TBW IBW 2mg/kg n=9 2mg/kg n=9 2mg/kg n=9 2mg/kg n=9 4mg/kg n=9 4mg/kg n=9 4mg/kg n=9 4mg/kg n=9 T...
Eligibility Criteria
Inclusion
- Inclusion criteria :
- ASA I-II-III
- Age 18 - 65 year
- Male or female
- BMI \> 30
- Exclusion criteria :
- Renal failure
- Liver dysfunction
- Breastfeeding female patients, or female patients without reliable contraception
- Neuromuscular disease
- Malignant hyperthermia or a family history of malignant hyperthermia
- Allergy for neuromuscular blocking agents or other medications used during general anesthesia
- Infectious disease or patients with fever
- Patients who already received rocuronium or sugammadex on the day of the study
Exclusion
Key Trial Info
Start Date :
January 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2012
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT01911520
Start Date
January 1 2011
End Date
June 1 2012
Last Update
July 13 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ghent University Hospital
Ghent, Belgium, 9000